Acura Pharmaceuticals, Inc. (ACUR) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerAcura Pharmaceuticals, Inc. (ACUR) trades at $0.0001. Acura Pharmaceuticals, Inc. focuses on developing and commercializing technologies to improve medication safety. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for ACUR: ACUR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Acura Pharmaceuticals, Inc. (ACUR) Healthcare & Pipeline Overview
Acura Pharmaceuticals, Inc. is a drug delivery company focused on developing and commercializing technologies for safer medication use, particularly in pain management and nasal decongestion. Its product portfolio includes Oxaydo and Nexafed, with ongoing research into abuse-deterrent formulations and collaborative agreements for global market expansion.
What Is the Investment Thesis for ACUR?
Acura Pharmaceuticals, Inc. presents a focused investment opportunity within the specialty pharmaceutical sector. The company's commitment to developing abuse-deterrent formulations addresses a critical need in pain management. Key value drivers include the potential for increased adoption of Oxaydo and Nexafed products, coupled with successful development and commercialization of its pipeline products, including LTX-03. The company's gross margin of 94.2% indicates strong pricing power. However, the company's negative profit margin of -56.2% and negative free cash flow of $-0.00B highlight the need for improved financial performance. Upcoming catalysts include potential regulatory approvals for new formulations and expansion of existing product lines. Potential risks include competition from established pharmaceutical companies and challenges in securing additional funding for research and development.
Based on FMP financials and quantitative analysis
ACUR Key Highlights
Gross Margin of 94.2% indicates strong pricing power in its product offerings.
- Negative Profit Margin of -56.2% reflects ongoing investments in research and development and commercialization efforts.
- Free Cash Flow of $-0.00B indicates the company is currently reliant on external funding.
- Beta of -54.49 suggests the stock price is inversely correlated with the market.
- The company has six additional opioid products in various stages of formulation development, signaling future growth potential.
Who Are ACUR's Competitors?
ACUR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.98 | -10.41% | — | |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.24 | -0.80% | $5.94M | — |
| BFRI Biofrontera Inc. | $1.01 | -2.40% | $13.0M | — |
| COSM COSM | $0.38 | -1.58% | $20.7M | — |
| QNTM Quantum BioPharma Ltd. | $3.44 | +0.44% | $22.0M | — |
| AYTU Aytu BioPharma, Inc. | $2.07 | -0.96% | $22.2M | — |
| TXMD TherapeuticsMD, Inc. | $2.05 | +0.99% | $23.7M | — |
| CPHI CPHI | $0.66 | +0.61% | $26.6M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACUR's Key Strengths?
Proprietary abuse-deterrent drug delivery technologies.
- Established partnerships with other pharmaceutical companies.
- Focus on a growing market segment (abuse-deterrent formulations).
- High gross margin (94.2%).
What Are ACUR's Weaknesses?
Negative profit margin (-56.2%).
- Negative free cash flow.
- Small number of employees (9).
- Limited product portfolio.
What Are the Key Risks for ACUR?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Competition from larger pharmaceutical companies with greater resources.
- Regulatory changes impacting opioid prescriptions and abuse-deterrent formulations.
- Challenges in securing funding for research and development.
- Dependence on key partnerships for product development and commercialization.
- Limited liquidity due to trading on the OTC market.
What Are ACUR's Competitive Advantages?
- Proprietary drug delivery technologies that enhance medication safety.
- Patents protecting its formulations and technologies.
- Established partnerships with other pharmaceutical companies.
- Expertise in developing abuse-deterrent formulations.
What Does ACUR Do?
Acura Pharmaceuticals, Inc., established in 1935 and headquartered in Palatine, Illinois, is dedicated to the research, development, and commercialization of pharmaceutical products designed to improve medication safety. The company's primary focus is on creating innovative drug delivery technologies that address the challenges associated with prescription drug abuse and misuse. Acura's product portfolio includes Oxaydo, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain. Additionally, the company offers Nexafed products, which are pseudoephedrine and acetaminophen tablets used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy medications. Acura Pharmaceuticals operates through strategic collaboration and license agreements with companies like Egalet US, Inc., Egalet Ltd., and Abuse Deterrent Pharma, LLC. These partnerships enable Acura to manufacture, commercialize, and further develop its product offerings, including LTX-03, an immediate-release tablet utilizing LIMITx technology. With a lean team of 9 employees, Acura Pharmaceuticals continues to innovate in the drug delivery space, aiming to provide safer and more effective medication options.
What Products and Services Does ACUR Offer?
- Develops and commercializes pharmaceutical products.
- Focuses on abuse-deterrent drug delivery technologies.
- Offers Oxaydo tablets for pain management.
- Provides Nexafed products for nasal decongestion.
- Engages in research and development of new formulations.
- Collaborates with other pharmaceutical companies for product development and commercialization.
How Does ACUR Make Money?
- Develops and patents proprietary drug delivery technologies.
- Manufactures and sells pharmaceutical products through partnerships and direct sales.
- Generates revenue through product sales and licensing agreements.
- Invests in research and development to expand its product pipeline.
What Industry Does ACUR Operate In?
Acura Pharmaceuticals, Inc. operates within the specialty pharmaceutical industry, which is characterized by a focus on developing niche products and innovative drug delivery systems. The industry is driven by the need for safer and more effective medications, particularly in areas such as pain management and abuse deterrence. The competitive landscape includes both large pharmaceutical companies and smaller, specialized firms. Acura's focus on abuse-deterrent formulations positions it within a growing segment of the market, driven by increasing concerns about opioid abuse and regulatory pressures to develop safer alternatives.
Who Are ACUR's Key Customers?
- Patients suffering from acute and chronic pain.
- Individuals seeking relief from nasal congestion.
- Pharmaceutical companies seeking to incorporate abuse-deterrent technologies into their products.
- Distributors and wholesalers of pharmaceutical products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Insider Activity
12 transactions · 0 purchases, 0 sales, 12 other transactions · 3 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Key Financial Metrics
Return on equity for Acura Pharmaceuticals, Inc. stands at 30.8%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.72 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Acura Pharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Acura Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Palatine, US. The company is led by CEO Robert Jones. ACUR has traded publicly since 1986.
ACUR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
ACUR Latest News
-
Acura Pharmaceuticals (OTCMKTS:ACUR) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?
defenseworld.net · Aug 22, 2026
ACUR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for ACUR.
Price Targets
Wall Street price target analysis for ACUR.
ACUR MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for ACUR; grades run from A+ (80-100) to F (below 30).
Leadership: Robert Jones
CEO
Robert Jones serves as the CEO of Acura Pharmaceuticals, Inc., leading a team of 9 employees. Therefore, a comprehensive background summary cannot be provided at this time.
Track Record: Due to the limited information available in the provided source data, a detailed track record of Robert Jones' key achievements, strategic decisions, and company milestones under his leadership cannot be accurately assessed.
ACUR OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Acura Pharmaceuticals, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity, price volatility, and lack of transparency compared to exchange-listed stocks.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume on the OTC market.
- Higher price volatility compared to exchange-listed stocks.
- Potential for limited or inconsistent financial disclosures.
- Increased risk of fraud or manipulation due to less regulatory oversight.
- Difficulty in obtaining accurate and timely information about the company.
- Verify the company's financial statements and SEC filings (if any).
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the company's capital structure and debt levels.
- Determine the company's compliance with regulatory requirements.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- The company has been incorporated since 1935, indicating a long operating history.
- Acura Pharmaceuticals, Inc. has existing commercialized products (Oxaydo and Nexafed).
- The company has collaboration and license agreements with other pharmaceutical companies.
- Acura Pharmaceuticals, Inc. is focused on developing abuse-deterrent formulations, addressing a significant public health concern.
- The company has a team of employees, suggesting ongoing operations.
What Investors Ask About Acura Pharmaceuticals, Inc. (ACUR) — Healthcare
How does Acura Pharmaceuticals, Inc. address the opioid crisis?
Acura Pharmaceuticals, Inc. addresses the opioid crisis by developing and commercializing abuse-deterrent formulations of opioid medications. Its Oxaydo tablets are designed to be more difficult to crush, snort, or inject, reducing the potential for misuse and abuse.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data as of 2026-03-16.
- OTC market data may be less reliable than exchange-listed data.